Extended Oral Antibiotics Market (Covid-19 update) Size, Demand, Growth, Challenges, Analysis and Forecasts To 2031

Global Extended Oral Antibiotics: Market Outlook

Extended oral antibiotics are one of the effective approach to prevent or control prosthetic joint infections, but the timing of delivery to optimize patient outcomes are debated. The other name for prosthetic joint infection (PJI) is peri-prosthetic infection, an infection involving the adjacent tissues and joint prosthesis. Prosthetic joint infection is one of the common etiologies and complications of implant failure after joint replacement surgeries and is putting a financial burden on the global healthcare system, and significant psychological and physical morbidity on patients. The majority of prosthetic joint infection (PJI) occurs within one year of surgery and are initiated through the introduction of microorganisms during the surgery, caused through either direct contact or aerosolized contamination of the periprosthetic tissue or prosthesis.

Request 100 Page Sample Report Now@https://www.factmr.com/connectus/sample?flag=S&rep_id=5630

The use of extended oral antibiotics has been found effective in minimizing the rate of prosthetic joint infections. It was observed that the prosthetic joint infections rate in high-risk patients who received antibiotics was less than the rate observed in low-risk patients. Thus, the extended oral antibiotic treatment may be an effective measure to prevent poor host factors. The rising number of total joint (hip (THA) and knee (TKA)) arthroplasty coupled with the growing advancements in novel therapies are expected to boost the global extended oral antibiotics market during the forecast period.

What are the factors boosting the Growth of the Extended Oral Antibiotics Market?

Extended oral antibiotics is likely to foster significant demand in the market due to the rising number of total joint arthroplasties (hip (THA) and knee (TKA) arthroplasty) and cases of prosthetic joint infections. Furthermore, the rising advancements in R&D for preventing or controlling prosthetic joint infections and introduction of immunoparticles, nanoparticles, novel antibiotics, photodynamic therapy, antimicrobial peptides, and lytic bacteriophages are some of the factors driving the growth of the global extended antibiotics market. Furthermore, the increasing geriatric population and antibiotics resistance is leading to the development of new antibiotics, which adds another factor driving the extended oral antibiotics market growth.

To receive extensive list of important regions, ask for TOC here@ https://www.factmr.com/connectus/sample?flag=T&rep_id=5630

The approaching reimbursement scenario is expected to have a positive impact on the extended oral antibiotics market growth. The government is the primary payer for the majority of total joint arthroplasties, through Medicare spending. Furthermore, in addition to improving patient care, preventing prosthetic joint infections may save costs to the Medicare plans. Several strategies and reimbursements are on the horizon that will impact provider compensation for hospitals and physicians.

What are the Key Challenges that may restrain the Growth of the Extended Oral Antibiotics Market?

However, there are some factors that can hinder the growth of global extended oral antibiotics market growth such as lack of trained pathologist in performing the histological analysis, especially in poor countries and awareness of the disease diagnosis treatment. Furthermore, the stringent regulations and lack of FDA approvals in some regions may impact the global extended oral antibiotics market growth.

Global Extended Oral Antibiotics: Market Outlook

Extended oral antibiotics are one of the effective approach to prevent or control prosthetic joint infections, but the timing of delivery to optimize patient outcomes are debated. The other name for prosthetic joint infection (PJI) is peri-prosthetic infection, an infection involving the adjacent tissues and joint prosthesis. Prosthetic joint infection is one of the common etiologies and complications of implant failure after joint replacement surgeries and is putting a financial burden on the global healthcare system, and significant psychological and physical morbidity on patients. The majority of prosthetic joint infection (PJI) occurs within one year of surgery and are initiated through the introduction of microorganisms during the surgery, caused through either direct contact or aerosolized contamination of the periprosthetic tissue or prosthesis.

The use of extended oral antibiotics has been found effective in minimizing the rate of prosthetic joint infections. It was observed that the prosthetic joint infections rate in high-risk patients who received antibiotics was less than the rate observed in low-risk patients. Thus, the extended oral antibiotic treatment may be an effective measure to prevent poor host factors. The rising number of total joint (hip (THA) and knee (TKA)) arthroplasty coupled with the growing advancements in novel therapies are expected to boost the global extended oral antibiotics market during the forecast period.

What are the factors boosting the Growth of the Extended Oral Antibiotics Market?

Extended oral antibiotics is likely to foster significant demand in the market due to the rising number of total joint arthroplasties (hip (THA) and knee (TKA) arthroplasty) and cases of prosthetic joint infections. Furthermore, the rising advancements in R&D for preventing or controlling prosthetic joint infections and introduction of immunoparticles, nanoparticles, novel antibiotics, photodynamic therapy, antimicrobial peptides, and lytic bacteriophages are some of the factors driving the growth of the global extended antibiotics market. Furthermore, the increasing geriatric population and antibiotics resistance is leading to the development of new antibiotics, which adds another factor driving the extended oral antibiotics market growth.

The approaching reimbursement scenario is expected to have a positive impact on the extended oral antibiotics market growth. The government is the primary payer for the majority of total joint arthroplasties, through Medicare spending. Furthermore, in addition to improving patient care, preventing prosthetic joint infections may save costs to the Medicare plans. Several strategies and reimbursements are on the horizon that will impact provider compensation for hospitals and physicians.

What are the Key Challenges that may restrain the Growth of the Extended Oral Antibiotics Market?

However, there are some factors that can hinder the growth of global extended oral antibiotics market growth such as lack of trained pathologist in performing the histological analysis, especially in poor countries and awareness of the disease diagnosis treatment. Furthermore, the stringent regulations and lack of FDA approvals in some regions may impact the global extended oral antibiotics market growth.

Share Your Requirements & Get Customized Reports@https://www.factmr.com/connectus/sample?flag=RC&rep_id=5630

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com

Visit Our Website: https://www.factmr.com

Research Insight:https://www.factmr.com/report/extended-oral-antibiotics-market

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.